Abstract
Improved knowledge and understanding of key aspects of cancer has led to the development of novel cancer therapeutics acting through complex pathways and mode of actions. The success of these novel cancer therapeutics is often difficult to predict using standard response criteria based on anatomic changes. Monitoring response to cancer therapy at molecular level using Positron Emission Tomography (PET) has gained popularity in recent years. PET allows longitudinal assessment of specific biological processes rather than just changes in anatomic changes in tumor size. In this review, we provide an overview on application for PET imaging to monitor cancer therapy with emphases on PET of tumor metabolism, cell proliferation, angiogenesis, hypoxia and receptor dynamics.
Keywords: Biomarker, Cancer, Molecular imaging, Monitoring response to therapy, Positron Emission Tomography.
Current Pharmaceutical Biotechnology
Title:PET Imaging to Monitor Cancer Therapy
Volume: 14 Issue: 7
Author(s): Gaurav Malviya and Tapan K. Nayak
Affiliation:
Keywords: Biomarker, Cancer, Molecular imaging, Monitoring response to therapy, Positron Emission Tomography.
Abstract: Improved knowledge and understanding of key aspects of cancer has led to the development of novel cancer therapeutics acting through complex pathways and mode of actions. The success of these novel cancer therapeutics is often difficult to predict using standard response criteria based on anatomic changes. Monitoring response to cancer therapy at molecular level using Positron Emission Tomography (PET) has gained popularity in recent years. PET allows longitudinal assessment of specific biological processes rather than just changes in anatomic changes in tumor size. In this review, we provide an overview on application for PET imaging to monitor cancer therapy with emphases on PET of tumor metabolism, cell proliferation, angiogenesis, hypoxia and receptor dynamics.
Export Options
About this article
Cite this article as:
Malviya Gaurav and Nayak K. Tapan, PET Imaging to Monitor Cancer Therapy, Current Pharmaceutical Biotechnology 2013; 14 (7) . https://dx.doi.org/10.2174/1389201014666131226104750
DOI https://dx.doi.org/10.2174/1389201014666131226104750 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Soy Saponins and the Anticancer Effects of Soybeans and Soy-Based Foods
Current Medicinal Chemistry - Anti-Cancer Agents DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design RNA-Mediated Therapeutics: From Gene Inactivation to Clinical Application
Current Topics in Medicinal Chemistry Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design Phytoestrogens in Postmenopause: The State of the Art from a Chemical, Pharmacological and Regulatory Perspective
Current Medicinal Chemistry Non Steroidal Estrogen Antagonists: Current Status and Future Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Bone Disease - Current Knowledge and Future Prospects
Current Genomics Skeletal Effects of Drugs to Treat Cancer
Current Drug Safety Eupatilin Inhibits the Proliferation and Migration of Prostate Cancer Cells through Modulation of PTEN and NF-κB Signaling
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Steroid Nuclear Receptor Family (Guest Editor: Pedro H.H. Hermkens)]
Current Medicinal Chemistry Biotransformation of Endocrine Disrupting Compounds by Selected Phase I and Phase II Enzymes – Formation of Estrogenic and Chemically Reactive Metabolites by Cytochromes P450 and Sulfotransferases
Current Medicinal Chemistry Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology Manipulation of Glycolysis in Malignant Tumors: Fantasy or Therapy?
Current Medicinal Chemistry Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design Quantitative Structure-Activity Relationship Studies: Understanding the Mechanism of Tyrosine Kinase Inhibition
Current Enzyme Inhibition Pharmacogenomics of Breast Cancer Targeted Therapy: Focus on Recent Patents
Recent Patents on DNA & Gene Sequences Rational Design of 5-Aminolevulinic Acid Derivatives Aimed at Improving Photodynamic Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents